Goldman Sachs analyst Salveen Richter maintained a Buy rating on Tango Therapeutics (TNGX – Research Report) today. The company’s shares closed today at $3.45.
According to TipRanks, Richter is a 5-star analyst with an average return of 23.0% and a 49.15% success rate. Richter covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Sarepta Therapeutics.
Tango Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.33.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.56 and a one-year low of $2.47. Currently, Tango Therapeutics has an average volume of 188.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Tango Therapeutics announces first patient dosed in TNG260 Phase 1/2 trial
- Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
- Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
- Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462
